Trevi Therapeutics Book Value 2011-2026 | TRVI

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Trevi Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
183 M	99.6 M	82.5 M	107 M	17.1 M	27.3 M	54.5 M	17.3 M	14.8 M	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
183 M	14.8 M	67.1 M

Quarterly Book Value Trevi Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
190 M	198 M	99.5 M	99.6 M	59 M	66.2 M	72.3 M	82.5 M	89.6 M	95.1 M	102 M	107 M	110 M	60.5 M	10.5 M	17.1 M	11.4 M	17.7 M	23.7 M	27.3 M	27.3 M	27.3 M	27.3 M	60 M	60 M	60 M	60 M	10.5 M	10.5 M	10.5 M	10.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
198 M	10.5 M	61.4 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	70.7 M	-	-	$ 86.2 M	USA
ACADIA Pharmaceuticals ACAD	733 M	$ 22.56	2.13 %	$ 3.74 B	USA
AlloVir ALVR	78.8 M	-	4.14 %	$ 49.1 M	USA
Applied Molecular Transport AMTI	60.8 M	-	-	$ 10.1 M	USA
Applied Therapeutics APLT	-17.1 M	-	-	$ 8.42 M	USA
Akebia Therapeutics AKBA	32.6 M	$ 1.43	3.62 %	$ 368 M	USA
argenx SE ARGX	7.32 B	$ 785.07	2.57 %	$ 25 B	Niderland
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Genfit SA GNFT	282 M	-	2.54 %	$ 160 B	France
Alnylam Pharmaceuticals ALNY	789 M	$ 327.25	2.42 %	$ 42.9 B	USA
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Aytu BioScience AYTU	124 M	$ 2.66	3.5 %	$ 16.7 M	USA
AVROBIO AVRO	94.7 M	-	1083.1 %	$ 745 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
AstraZeneca PLC AZN	48.7 B	-	-	$ 96.9 B	Britain
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
BeiGene, Ltd. BGNE	4.36 B	-	0.49 %	$ 251 B	Cayman-islands
Alterity Therapeutics Limited ATHE	35.5 M	$ 3.9	3.7 %	$ 9.38 B	Australia
CymaBay Therapeutics CBAY	292 M	-	-	$ 3.45 B	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Amphastar Pharmaceuticals AMPH	789 M	$ 20.4	-0.87 %	$ 954 M	USA
Aquestive Therapeutics AQST	-33.7 M	$ 4.18	1.21 %	$ 447 M	USA
Avid Bioservices CDMO	60.9 M	-	-	$ 789 M	USA
Cidara Therapeutics CDTX	163 M	-	-	$ 1.41 B	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Arcutis Biotherapeutics ARQT	189 M	$ 24.61	5.76 %	$ 3.13 B	USA
Cabaletta Bio CABA	112 M	$ 3.09	0.65 %	$ 310 M	USA
Checkpoint Therapeutics CKPT	-12.6 M	-	-	$ 169 M	USA
Aeterna Zentaris AEZS	13.2 M	-	5.93 %	$ 314 M	Canada
Checkmate Pharmaceuticals CMPI	69.5 M	-	-	$ 231 M	USA
AgeX Therapeutics AGE	-37 K	-	-10.17 %	$ 12.2 K	USA
Concert Pharmaceuticals CNCE	112 M	-	-	$ 401 M	USA
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
Autolus Therapeutics plc AUTL	178 M	$ 1.49	9.56 %	$ 397 M	Britain
CTI BioPharma Corp. CTIC	-17.6 M	-	-	$ 1.2 B	USA
AIkido Pharma AIKI	69.4 M	-	1.93 %	$ 17.4 M	USA
Aptose Biosciences APTO	-27.2 M	-	-45.71 %	$ 1.2 M	Canada
Cyclacel Pharmaceuticals CYCCP	6.84 M	-	-4.36 %	$ 27 M	USA
Deciphera Pharmaceuticals DCPH	351 M	-	-	$ 2.18 B	USA
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
Dynavax Technologies Corporation DVAX	597 M	-	-	$ 2.02 B	USA
Forte Biosciences FBRX	61 M	$ 26.27	0.38 %	$ 340 M	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
Akari Therapeutics, Plc AKTX	28.3 M	$ 3.88	2.11 %	$ 261 B	Britain
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA